Apellis Pharmaceuticals (APLS) Revenue
Market Cap: $2.21B
Avg Volume: 2.01M
Industry: Biotechnology
Sector: Healthcare
What is Apellis Pharmaceuticals's Revenue?
Apellis Pharmaceuticals's quarterly revenue as of Q4 2024 is $212.53M.
Apellis Pharmaceuticals's annual revenue for the fiscal year 2024 is $709.95M.
Related metrics for Apellis Pharmaceuticals (quarterly):
- Cost of Revenue: $40.86M
- Gross Profit: $171.67M
- Gross Profit Ratio: 80.78%
- Revenue Per Share: $1.72
- Revenue Growth: 7.98%
Apple's quarterly revenue was $212.53M, with a cost of revenue of $40.86M, which leaves $171.67M gross profit and a gross profit ratio of 80.78%.
Related metrics for Apellis Pharmaceuticals (annual):
- Cost of Revenue: $117.72M
- Gross Profit: $592.23M
- Gross Profit Ratio: 83.42%
- Revenue Per Share: $5.73
- Revenue Growth: 79.01%
Apple's annual revenue was $709.95M, with a cost of revenue of $117.72M, which leaves $592.23M gross profit and a gross profit ratio of 83.42%.
Understanding Revenue
Revenue is the total amount of income generated by the sale of goods or services related to the company's primary operations. It is often referred to as the "top line" because it sits at the top of the income statement.
End of Year Revenue
The table below shows the revenue for each fiscal year, with the latest data available for 2024.
| Year | Revenue | Change |
|---|---|---|
| 2024 | $709.95M | 79.01% |
| 2023 | $396.59M | 425.83% |
| 2022 | $75.42M | 13.31% |
| 2021 | $66.56M | -73.44% |
| 2020 | $250.65M | N/A |
| 2019 | $- | N/A |
| 2018 | $- | N/A |
| 2017 | $- | N/A |
| 2016 | $- | N/A |
| 2015 | $- | N/A |
| 2014 | $- | N/A |
| 2013 | $- | N/A |
Related Metrics
Explore detailed financial metrics and analysis for APLS.